Current Diagnosis and Management of Small-Cell Lung Cancer.

Détails

ID Serval
serval:BIB_AA5A2D533FC4
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Current Diagnosis and Management of Small-Cell Lung Cancer.
Périodique
Mayo Clinic proceedings
Auteur⸱e⸱s
Wang S., Zimmermann S., Parikh K., Mansfield A.S., Adjei A.A.
ISSN
1942-5546 (Electronic)
ISSN-L
0025-6196
Statut éditorial
Publié
Date de publication
08/2019
Peer-reviewed
Oui
Volume
94
Numéro
8
Pages
1599-1622
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non-small-cell lung cancer. SCLC has high metastatic potential, resulting in a clinically poor prognosis. Early concurrent chemo-radiation is the standard of care for limited-stage SCLC (LS-SCLC). Prophylactic cranial irradiation (PCI) is recommended for patients with LS-SCLC without progression of disease after initial therapy. A combination of etoposide and cisplatin or carboplatin remains the mainstay of first-line treatment for ES-SCLC, with the addition of atezolizumab, now becoming standard. Most SCLCs initially respond to therapy but almost invariably recur. Topotecan and amrubicin (in Japan) remain the primary chemotherapy options for relapsed SCLC. Immunotherapy, including nivolumab with or without ipilimumab, is now available for refractory disease. In general, the poor prognosis of SCLC has not improved significantly for more than 3 decades. Recently, next-generation molecular profiling studies have identified new therapeutic targets for SCLC. A variety of proapoptotic agents, compounds capitalizing on DNA-repair defects, immunotherapy agents, and antibody-drug conjugates are being evaluated in SCLC, with a number of them showing early promise.
Mots-clé
Aged, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Biological Products/therapeutic use, Carcinoma, Non-Small-Cell Lung/diagnosis, Carcinoma, Non-Small-Cell Lung/mortality, Carcinoma, Non-Small-Cell Lung/therapy, Chemoradiotherapy/methods, Disease Management, Disease-Free Survival, Female, Humans, Immunotherapy/methods, Japan, Lung Neoplasms/diagnosis, Lung Neoplasms/drug therapy, Lung Neoplasms/mortality, Male, Middle Aged, Neoplasm Invasiveness/pathology, Neoplasm Staging, Prognosis, Risk Assessment, Survival Analysis
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/08/2019 15:43
Dernière modification de la notice
11/01/2020 7:16
Données d'usage